Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
about
Getting TRAIL back on track for cancer therapyStructural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5Identification of miRNA-7 by genome-wide analysis as a critical sensitizer for TRAIL-induced apoptosis in glioblastoma cells.Examination of survivin expression in 50 chordoma specimens--A histological and in vitro study.Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.New targets for the treatment of follicular lymphoma.Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerModulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)Promising novel therapies for the treatment of endometrial cancerWill targeting insulin growth factor help us or hurt us?: An oncologist's perspectivePredominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesStrong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivoDacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis.The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious DiseasesA cell-based high-throughput screen to identify synergistic TRAIL sensitizers.Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathwayThirteen-week Intravenous Toxicity Study of a Novel Humanized Anti-Human Death Receptor 5 Monoclonal Antibody, CS-1008, in Cynomolgus Monkeys.Targeted ovarian cancer treatment: the TRAILs of resistance.On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma.Targeted therapy in Ewing sarcoma.Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer.Lung cancer: Biology and treatment options.The TRAIL to targeted therapy of breast cancer.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.TRAIL-receptor antibodies as a potential cancer treatment.Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.Molecular targeted therapies for pancreatic cancer.
P2860
Q27027460-E27F1207-6514-4F29-8829-6900D6B35635Q27649718-5192C95E-FEA3-4E33-BF8B-0ED44C0E1714Q30854013-26DDDA18-3D62-4943-A929-C5D75B0F1525Q33275528-20574FA3-37BE-484F-BDD6-23A4D0E8A056Q33421148-824445E0-23F4-4550-A21B-CAC8A13353BCQ33587396-A5AB692A-487E-43CF-A46D-EDE5BB588AFBQ33658593-58D94440-610A-4DC7-BF33-8F3E1BE15E20Q33805582-25E89B57-F5B6-45CF-9D5D-BCE555ED480EQ33906524-3A3E6FBD-E7B7-473E-A59D-EF5C8B6EC74CQ33920661-2BF7FB92-BE70-4E88-B2EA-12C1C8CE6FC4Q33926307-F73A8D3F-1298-4162-B1F7-BBA3ACB994C2Q34132999-D98966B2-FCA8-45B7-9DF7-CDDDA9077FD8Q34139691-AEF2E8C2-56E3-4C2C-8ED0-E63BF1CE0E46Q34163784-2EDDBE94-97BF-42B5-AD31-9C61CD08BBE6Q34256933-7A6F6FF4-6A19-4682-9292-86A7F25F6E91Q34429203-C2F13B30-7DC0-4118-A3AA-405C63095BD6Q34433792-79994504-7E00-4E4F-BAA0-9A6D2CD6E402Q34775475-DA0F633D-5E6F-4F71-8DEB-C5761BF9EC50Q35038107-89BE6D6F-D5D8-4523-94A8-A512F5FE54B6Q35050195-CF0A9ADB-27B8-4006-AF1A-6F78FE9E60ABQ35158520-7FAAC7C4-0D67-4E35-BB81-20328638E1CFQ35172090-4F1DE3FF-21EF-47E3-834F-C6E76F60A3B4Q35200982-C2FA84FF-A34E-4C7F-A361-96E445A15565Q35595688-90552272-57CA-4E3A-81B9-D760268EEA2EQ35603999-AC09A6F7-F737-4FD0-9E32-05CE8C0270E6Q35609438-793EADEE-D4FD-4126-A18E-6C1B8346B6C0Q35853714-10AE2C41-FC27-46AD-B702-DDDEA043C5B1Q35936863-C4C944E0-62B8-42D5-8956-F857E6FE225AQ35951059-779668D7-452B-43A5-87F8-F35915E12A23Q35967192-029A20C9-7475-4CE7-8C7A-3F27E3EE7B0CQ36011879-DE7C5989-F168-4660-A68D-AD6616D75963Q36194859-F3E0FDB3-566D-4FC5-BB40-530364C60FC3Q36328370-13D1F38A-2AED-4877-8928-91372A1EF834Q36511919-FBA2CC5E-FB98-49EE-9C85-416AAF11E1BCQ36731174-FA5AAE35-A311-4D11-8EF0-B0F2F38A65FAQ36825315-8A0431C7-A699-49A3-B8B6-13A1D3405A68Q36837553-9B97B3D1-5B11-48A8-B3EB-47FFE8AB197CQ36895805-DCED0FDA-6B5C-44F5-9490-584EAF0146E4Q36938811-30B81E53-4D40-4C6F-8791-348A513F5F0FQ36944441-72B974D9-64B1-46A3-8C5F-49CAC0EB0AC6
P2860
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Phase I pharmacokinetic and bi ...... is-inducing ligand receptor-1.
@en
type
label
Phase I pharmacokinetic and bi ...... is-inducing ligand receptor-1.
@en
prefLabel
Phase I pharmacokinetic and bi ...... is-inducing ligand receptor-1.
@en
P2093
P356
P1476
Phase I pharmacokinetic and bi ...... is-inducing ligand receptor-1.
@en
P2093
Alfred Corey
Amita Patnaik
Anthony W Tolcher
Kristin Padavic
Monica Mita
Monique Hill
Neal J Meropol
Norma Lynn Fox
Roger B Cohen
Theresa Mays
P304
P356
10.1200/JCO.2006.08.8898
P407
P577
2007-04-01T00:00:00Z